Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01575925 | Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) | PHASE1 | COMPLETED | 25 | — | — | Jun 1, 2012 | Aug 7, 2018 | Nov 4, 2022 | 9 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| 4 mg Oral POM + 40 mg Oral DEX | EXPERIMENTAL | Oral POM at 4 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle |
| 2 mg Oral POM + 40 mg Oral DEX | EXPERIMENTAL | Oral POM at 2 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle |
| Name | Type | Description |
|---|---|---|
| 4 mg Oral POM + 40 mg Oral DEX | DRUG | - |
| 2 mg Oral POM + 40 mg Oral DEX | DRUG | - |
Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: 1. Must be ≥ 18 years at the time of signing the informed consent form 2. Must understand and voluntarily sign an informed consent document prior to any study-related assessments/procedures 3. Must be abl...